A team of Stanford researchers has identified a group of small molecules that can prevent or reverse T cell exhaustion, thereby increasing the effectiveness of adoptive T cell therapies to fight cancer or chronic infections.
A Stanford research team has patented methods that can prevent or reverse T cell exhaustion, thereby increasing the effectiveness of adoptive T cell therapies to fight cancer or chronic infections.
Stanford inventors have developed a nanoparticle containing the toll-like receptor agonist (TLR7-NP) that elicits a potent anti-tumor immune response in multiple cancer types without inducing undesired systemic inflammation and toxicity.